Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Core Insights - Editas Medicine, Inc. has announced its three-year strategic priorities and key milestones for 2025, focusing on in vivo gene editing for serious diseases [1][4] - The company aims to establish itself as a leader in in vivo programmable gene editing, supported by recent scientific breakthroughs and preclinical data [2][4] In Vivo Gene Editing Developments - New in vivo preclinical proof of concept data has been achieved in non-human primates for editing hematopoietic stem cells (HSCs) and liver cells, demonstrating the potential of the gene upregulation strategy [3][4] - The company has successfully demonstrated high efficiency in delivering gene editing to extrahepatic cell types using its proprietary lipid nanoparticle (LNP) targeting platform in humanized mice [3][5] 2025 Key Milestones - Anticipated milestones for 2025 include declaring two in vivo development candidates, presenting further in vivo HSC data, and establishing an additional target cell type/tissue [4][12] - The company plans to submit at least one investigational new drug (IND) application by mid-2026 and commence late-stage trials for at least one asset by the second half of 2027 [12] Financial Position - As of December 31, 2024, the company reported approximately $270 million in cash, cash equivalents, and marketable securities, with a cash runway extending into Q2 2027 [8] Upcoming Presentation - The company will present its new in vivo preclinical data and strategic priorities at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [9]